Developed by Shray Alag, The Harker School
Sections: Correlations,
Clinical Trials, and HPO
Navigate: Clinical Trials and HPO
| Name (Synonyms) | Correlation | |
|---|---|---|
| drug2688 | On-line exercise and education Wiki | 1.00 |
| Name (Synonyms) | Correlation | |
|---|---|---|
| D020370 | Osteoarthritis, Knee NIH | 0.45 |
| D010003 | Osteoarthritis, NIH | 0.41 |
| Name (Synonyms) | Correlation | |
|---|---|---|
| HP:0005086 | Knee osteoarthritis HPO | 0.45 |
| HP:0002758 | Osteoarthritis HPO | 0.41 |
Navigate: Correlations HPO
There is one clinical trial.
Due to enforced social distancing as a direct consequence of the COVID-19 pandemic, many on-site health care services are unavailable. This study seeks to investigate the relative effectiveness of an alternative on-line delivery model of exercise and education compared to on-site delivery in patients with knee osteoarthritis.
Description: Summary score from the Knee injury and Osteoarthritis Outcome Score, short version (KOOS 12). The summary score is calculated as the average score from the KOOS 12 subscales pain, function and quality of life (QOL), ranging from 0 (worst) to 100 (best).
Measure: Knee impact summary Time: Primary follow-up point: Change from baseline to completion of GLA:D program (an average of three months). Secondary follow-up point: 12 monthsDescription: Fast-paced walking ability is recorded by the physiotherapists and evaluated using the 40-m fast-paced walk test.
Measure: Fast-paced walking ability Time: Primary follow-up point: Change from baseline to completion of GLA:D program (an average of three months)Description: Chair-stand ability is recorded by the physiotherapists and evaluated using the 30-s chair-stand test.
Measure: Chair-stand ability Time: Primary follow-up point: Change from baseline to completion of GLA:D program (an average of three months)Description: Patients self-report of function during daily life using the subscale function from the KOOS 12 questionnaire with scores ranging from 0 (worst) to 100 (best).
Measure: Self-reported function Time: Primary follow-up point: Change from baseline to completion of GLA:D program (an average of three months). Secondary follow-up point: 12 monthsDescription: Patients self-report of pain using the subscale pain from the KOOS 12 questionnaire with scores ranging from 0 (worst) to 100 (best).
Measure: Self-reported pain Time: Primary follow-up point: Change from baseline to completion of GLA:D program (an average of three months). Secondary follow-up point: 12 monthsDescription: Patients self-report of quality of life using the subscale quality of life from the KOOS 12 questionnaire with scores ranging from 0 (worst) to 100 (best).
Measure: Self-reported quality of life Time: Primary follow-up point: Change from baseline to completion of GLA:D program (an average of three months). Secondary follow-up point: 12 monthsDescription: Mean pain intensity during the last week in the most affected knee is evaluated on a 100 mm visual analogue scale (VAS) with terminal descriptors of 'no pain' (0 mm) and 'maximum pain' (100 mm).
Measure: Pain intensity Time: Primary follow-up point: Change from baseline to completion of GLA:D program (an average of three months). Secondary follow-up point: 12 monthsDescription: Patients self-report of time spent (frequency and duration) on structured physical activity and exercise.
Measure: Physical activity and exercise Time: Primary follow-up point: Change from baseline to completion of GLA:D program (an average of three months). Secondary follow-up point: 12 monthsDescription: Patients self-report of satisfaction with the GLA:D program.
Measure: Patient satisfaction Time: Primary follow-up point: Completion of GLA:D program (an average of three months). Secondary follow-up point: 12 monthsDescription: Patients self-reporting if, how and where they have continued exercising.
Measure: Continuation of exercise Time: Follow-up point: 12 monthsDescription: Patients self-report their current activity levels using the University of California, Los Angeles (UCLA) activity scale, ranging from 1 (inactive, dependent on others) to 10 (regular participation in high-impact sports).
Measure: Self-reported activity levels Time: Primary follow-up point: Change from baseline to completion of GLA:D program (an average of three months). Secondary follow-up point: 12 monthsDescription: Patients self-report of use of acquired skills and knowledge from the GLA:D program.
Measure: Usage of what was learned during GLA:D Time: Primary follow-up point: Completion of GLA:D program (an average of three months). Secondary follow-up point: 12 monthsDescription: Patients self-report of how they handle flare-ups in their knee OA symptoms.
Measure: Symptom management Time: Primary follow-up point: Change from baseline to completion of GLA:D program (an average of three months). Secondary follow-up point: 12 monthsDescription: Intake of painkillers is evaluated by the physiotherapist asking the patients about intake of any joint related medication. If taking painkillers, the patients are asked which type and whether or not they were taken because of their knee pain.
Measure: Intake of pain killers Time: Primary follow-up: Change from baseline to completion of GLA:D program (an average of three months).Description: Patients self-report of sick leave due to knee symptoms.
Measure: Sick leave Time: Follow-up points: Baseline and 12 monthsDescription: Patients self-report of their health situation using EuroQol, 5 dimensions, 5 levels (EQ-5D-5L) score (-0.624 to 1; worst to best).
Measure: Health-related quality of life, index score Time: Primary follow-up point: Change from baseline to completion of GLA:D program (an average of three months). Secondary follow-up point: 12 monthsDescription: Patients self-report of their health situation using the EuroQol visual analogue scale (EQ VAS), ranging from 0-100 (worst to best).
Measure: Health-related quality of life, visual analogue scale Time: Primary follow-up point: Change from baseline to completion of GLA:D program (an average of three months). Secondary follow-up point: 12 monthsDescription: Patients self-report of current knee condition compared to before participation in GLA:D, scored on a 7-point likert scale (much worse to much better).
Measure: Global perceived effect Time: Primary follow-up point: Completion of GLA:D program (an average of three months). Secondary follow-up point: 12 monthsDescription: Patients self-report of pain during each exercise session, rated using a numeric pain rating scale (NPRS) 0-10, with zero representing no pain and 10 representing extreme pain.
Measure: Pain during exercise (only for on-line group) Time: Immediately prior to, and immediately after each exercise sessionAlphabetical listing of all HPO terms. Navigate: Correlations Clinical Trials
Data processed on September 26, 2020.
An HTML report was created for each of the unique drugs, MeSH, and HPO terms associated with COVID-19 clinical trials. Each report contains a list of either the drug, the MeSH terms, or the HPO terms. All of the terms in a category are displayed on the left-hand side of the report to enable easy navigation, and the reports contain a list of correlated drugs, MeSH, and HPO terms. Further, all reports contain the details of the clinical trials in which the term is referenced. Every clinical trial report shows the mapped HPO and MeSH terms, which are also hyperlinked. Related HPO terms, with their associated genes, protein mutations, and SNPs are also referenced in the report.
Drug Reports MeSH Reports HPO Reports